Hommels TM, et al. - In a dedicated prospective, international study (ABSORB DM Benelux Study), midterm safety and effectiveness of everolimus-eluting bioresorbable scaffolds (EE-BRS) in diabetes mellitus (DM) patients was assessed. Major adverse cardiac events (a composite of all-cause death, any myocardial infarction, and ischemic-driven target vessel revascularization), target lesion failure (a composite of cardiac death, target vessel MI, and ischemic-driven target lesion revascularization), and definite or probable scaffold thrombosis (ScT) were assessed in DM patients that received ≥ 1 EE-BRS for any indication. For 3 years, follow-up was performed in 150 DM patients and 188 treated lesions. The midterm safety and efficacy outcomes of EE-BRS were comparable to those seen with modern drug-eluting stent (DES). New-generation EE-BRS might be a substitute to metallic DES in the treatment of DM patients.